Phase 2 Study of Elranatamab Plus Isatuximab in Relapsed and Refractory Multiple Myeloma

MGH is launching an open-label phase 2 trial evaluating subcutaneous elranatamab in combination with investigational isatuximab for RRMM patients after at least two prior therapies, including IMiDs and proteasome inhibitors. The study’s dosing schedule is designed to optimize efficacy and treatment convenience.